Aetion is a health care technology company that delivers real-world evidence for life sciences, payers, providers, and regulatory agencies. The Aetion Evidence Platform analyzes data from the real world to produce transparent, rapid, and scientifically validated answers on treatments, costs, and outcomes. Founded by Harvard Medical School faculty members with decades of experience in epidemiology and health outcomes research, Aetion informs health care’s most critical decisions — what works best, for whom, and when — to guide treatment development, commercialization, and payment innovation into health care’s modern era. Aetion is based in New York City and backed by investors including New Enterprise Associates (NEA), Flare Capital Partners, Lakestar, and Town Hall Ventures. Learn more at aetion.com, follow us at @aetioninc, and subscribe to our monthly newsletter, The Evidence Digest, at https://www.aetion.com/evidence-digest.
B2B
101 to 250
Series B
$96.3 M
Scaling Up
2015
Pharmaceuticals and Medical Products
Life Sciences Tools & Services
Healthcare
N/A
Revenue Growth
Analytics
IT and Security
Service
Yes
Active
Machine Learning
Machine Perception
Knowledge Representation and Reasoning
N/A
Software
N/A
May 2020
- FDA Partners with Aetion to Gather Real-World Data on the Coronavirus
Apr 2020
- Aetion, HealthVerity Launch New Tools for Assessing COVID-19 Treatments
May 2019
- Aetion Presentation Awarded ?Best Podium? at ISPOR 2019
Engagement Manager
New York, New York
Senior Scientist (Epidemiology)
New York, New York
Scientist (Epidemiology)
New York, New York
Science Prospects
New York, New York
Director, Science
New York, New York
AI/ML Professionals
5
1
$110M
Company was founded 2015 and it took almost 6 years (May 2021) to raise first external round
Investors
Interested in researching Aetion?
We have plenty of data and we can help. Our deal sourcing platform can help you perform more research about Aetion
